Somatostatin Receptor-Binding Peptides Labeled with Technetium-99m:  Chemistry and Initial Biological Studies

1996 ◽  
Vol 39 (7) ◽  
pp. 1361-1371 ◽  
Author(s):  
Daniel A. Pearson ◽  
John Lister-James ◽  
William J. McBride ◽  
David M. Wilson ◽  
Lawrence J. Martel ◽  
...  
2007 ◽  
Vol 50 (6) ◽  
pp. 1354-1364 ◽  
Author(s):  
John E. Cyr ◽  
Daniel A. Pearson ◽  
David M. Wilson ◽  
Carol A. Nelson ◽  
Mary Guaraldi ◽  
...  

2000 ◽  
Vol 21 (6) ◽  
pp. 590
Author(s):  
R. Manchanda ◽  
M. T. Azure ◽  
D. A. Pearson ◽  
D. M. Wilson ◽  
B. R. Moyer ◽  
...  

Author(s):  
R. Quirion ◽  
J.C. Martel ◽  
Y. Robitaille ◽  
P. Etienne ◽  
P. Wood ◽  
...  

Abstract:Multiple neurotransmitter systems are affected in senile dementia of the Alzheimer's type (SDAT). Among them, acetylcholine has been most studied. It is now well accepted that the activity of the enzyme, choline acetyltransferase (ChAT) is much decreased in various brain regions including the frontal and temporal cortices, hippocampus and nucleus basalis of Meynert (nbm) in SDAT. Cortical M2-muscarinic and nicotinic cholinergic receptors are also decreased but only in a certain proportion (30-40%) of SDAT patients. For other systems, it appears that cortical serotonin (5-HT)-type 2 receptor binding sites are decreased in SDAT. This diminution in 5-HT2 receptors correlates well with the decreased levels of somatostatin-like immunoreactive materials found in the cortex of SDAT patients. Cortical somatostatin receptor binding sites are decreased in about one third of SDAT patients. Finally, neuropeptide Y and neuropeptide Y receptor binding sites are distributed in areas enriched in cholinergic cell bodies and nerve fiber terminals and it would be of interest to determine possible involvement of this peptide in SDAT. Thus, it appears that multi-drug clinical trials should be considered for the treatment of SDAT.


2019 ◽  
Vol 68-69 ◽  
pp. 1-13 ◽  
Author(s):  
Vanessa A. Sanders ◽  
David Iskhakov ◽  
Dalya Abdel-Atti ◽  
Matthew Devany ◽  
Michelle C. Neary ◽  
...  

1997 ◽  
Vol 24 (3) ◽  
pp. 316-319 ◽  
Author(s):  
Bernd Johannsen ◽  
Ralf Berger ◽  
Peter Brust ◽  
Hans-Juergen Pietzsch ◽  
Matthias Scheunemann ◽  
...  

2002 ◽  
Vol 307 (1) ◽  
pp. 159-166 ◽  
Author(s):  
Elizabeth T Birzin ◽  
Susan P Rohrer

1995 ◽  
Vol 268 (2) ◽  
pp. E343-E348
Author(s):  
I. Alvaro-Alonso ◽  
B. Colas ◽  
J. P. Esteve ◽  
C. Susini ◽  
E. Arilla

In the present study we found that exocrine pancreatic hyperplasia observed after proximal small bowel resection is accompanied by an increase in pancreatic somatostatin (SS) content at 1 mo and an increase in the number of SS receptors at 2 wk and 1 mo after intestinal surgery. At 6 mo after small bowel resection SS content and SS receptors had returned to control values. However, the original increase in SS receptor number was accompanied by a decrease in the ability of SS to inhibit forskolin-stimulated adenylyl cyclase (AC) activity. In addition, the ability of 5'-guanylylimidodiphosphate (a nonhydrolyzable GTP analogue) to inhibit SS receptor binding was decreased in pancreatic acinar membranes from enterectomized rats at 2 wk and 1 mo after jejunoileal resection. These data suggest that there is an abnormality in the integrity of SS receptor binding site-G protein interactions and would explain the decreased inactivation of AC by SS at 2 wk and 1 mo after proximal small bowel resection.


1997 ◽  
Vol 24 (3) ◽  
pp. 316-319
Author(s):  
Bernd Johannsen ◽  
Ralf Berger ◽  
Peter Brust ◽  
Hans-Juergen Pietzsch ◽  
Matthias Scheunemann ◽  
...  

2002 ◽  
Vol 293 (4) ◽  
pp. 1279-1286 ◽  
Author(s):  
Ingrid N. Michon ◽  
Louis C. Penning ◽  
Tom J.M. Molenaar ◽  
Theo J.C. van Berkel ◽  
Erik A.L. Biessen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document